Janssen Pharmaceutica Nv

Galapagos Nv

Christopher John Love

Nele Vandermaesen

Peter Jacobus Johannes Antonius Buijnsters

Ludwig Paul Cooymans

Julien Georges Pierre-Olivier Doyon

Jean-Pierre Andre Marc Bongartz

Robert Jozef Maria Hendrickx

Erwin Coesemans

Gustaaf Maria Boeckx

Guy Rosalia Eugeen Van Lommen

Marcel Jozef Maria Van Der Aa

Lieven Meerpoel

Joannes Theodorus Maria Linders

Bruno Schoentjes

Alain Philippe Poncelet

Luc August Laurentius Ver Donck

Christel Jeanne Marie Menet

Jean-Pierre André Marc Bongartz

Steven Emiel Van Der Plas

Reginald Christophe Xavier Brys

Jean-Michel Lefrancois

Oscar Mammoliti

Agnès Marie Joncour

Pieter Isabelle Roger Claes

Jean Pierre Frans Van Wauwe

Frédéric Gilbert Labéguère

Giovanni Alessandro Tricarico

Jean-Michel Lefrançois

Brigitte Allart

Marina Lucie Louise Cools

Maxim Maria Paul De Wachter

Raphaël Jean Joël Geney

Benoît Antoine Schmitt

Frédéric Gilbert LABÉGUÈRE

A compound according to Formula I: wherein R, L, Cy, R, R, R, and Rare as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions, pain, neuroinflammatory conditions, neurodegenerative conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, cardiovascular diseases, leukemia, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.

Dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders

The present invention discloses compounds according to Formula I: wherein R, R, and Cy are as defined herein. The present invention relates to compounds inhibiting IRAK family kinases, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases and/or proliferative diseases by administering the compound of the invention.

6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-B]pyridin-3-yl]-nicotinonitrile derivatives and their use as IRAK inhibitors

The present invention relates to a compound of formula (I) including any stereochemically isomeric form thereof, wherein the substituents are as defined in the specification and the claims; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof; or a pharmaceutically acceptable salt thereof. The claimed compounds are useful for the treatment of a disease, the treatment of which is affected, mediated or facilitated by activating the GHS1A-r receptor. The invention also relates to pharmaceutical compositions thereof and processes for the preparation thereof.

Benzocycloheptane and benzoxepine derivatives

The present invention relates to a compound of formula (I) including any stereochemically isomeric form thereof, wherein the substituents are as defined in the specification and the claims; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof;  The claimed compounds are useful for the treatment of a disease, the treatment of which is affected, mediated or facilitated by activating the GHS1A-r receptor. The invention also relates to pharmaceutical compositions thereof and processes for the preparation thereof.

The present invention relates to a compound of formula (I) including any stereochemically isomeric form thereof, wherein the substituents are as defined in the specification and the claims; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof;provided that the compound is other than or a pharmaceutically acceptable salt thereof. The claimed compounds are useful for the treatment of a disease, the treatment of which is affected, mediated or facilitated by activating the GHS1A-r receptor. The invention also relates to pharmaceutical compositions thereof and processes for the preparation thereof.

This invention concerns the use of a compound of formula (I') a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein Z is halo; Calkyl; Calkylcarbonyl; Calkyloxycarbonyl; aminocarbonyl; Calkyl substituted with hydroxy, carboxyl, cyano, amino, amino substituted with piperidinyl, amino substituted with Calkyl substituted piperidinyl, mono- or di(Calkyl)amino, aminocarbonyl, mono- or di(Calkyl)aminocarbonyl, Calkyloxycarbonyl, Calkyloxy, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl; polyhaloCalkyl; cyano; amino; mono- or di(Calkyl)aminocarbonyl; Calkyloxycarbonyl; Calkylcarbonyloxy; aminoS(&#x2550;O)&#x2014;; mono- or di(Calkyl)aminoS(&#x2550;O); &#x2014;C(&#x2550;N&#x2014;R)NRR; Q is optionally substituted Ccycloalkyl, phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzthiazolyl, benzoxazolyl, benzimidazolyl, indazolyl, or imidazopyridyl, or Q is a radical of formula L is optionally substituted phenyl or an optionally substituted monocyclic 5 or 6-membered partially saturated or aromatic heterocycle or a bicyclic partially saturated or aromatic heterocycle; aryl is optionally substituted phenyl; for the manufacture of a medicament for the prevention or the treatment of inflammatory and/or auto-immune diseases mediated through TNF-&#x3b1; and/or IL-12.

2-amino-4,5-trisubstituted thiazolyl derivatives

The present invention relates to a compound of formula (I) having CCR2 receptor antagonistic properties, particularly anti-inflammatory properties.

Mercaptoimidazoles as CCR2 receptor antagonists

This invention concerns the use of a compound of formula (I'), a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein Z is halo; Calkyl; Calkylcarbonyl; Calkyloxy -carbonyl; aminocarbonyl; Calkyl substituted with hydroxy, carboxyl, cyano, amino, amino substituted with piperidinyl, amino substituted with Calkyl substituted piperidinyl, mono- or di(Calkyl)amino, aminocarbonyl, mono- or di(Calkyl)aminocarbonyl, Calkyloxycarbonyl, Calkyloxy, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl; polyhaloCalkyl; cyano; amino; mono- or di(Calkyl)aminocarbonyl; Calkyloxycarbonyl; Calkylcarbonyloxy; aminoS(&#x2550;O)&#x2014;; mono- or di(Calkyl)aminoS(&#x2550;O); &#x2014;C(&#x2550;N&#x2014;R)NRR; Q is optionally substituted Ccycloalkyl, phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzthiazolyl, benzoxazolyl, benzimidazolyl, indazolyl, or imidazopyridyl, or Q is a radical of formula (b-1), (b-2), or (b-3), L is optionally substituted phenyl or an optionally substituted monocyclic 5 or 6-membered partially saturated or aromatic heterocycle or a bicyclic partially saturated or aromatic heterocycle; aryl is optionally substituted phenyl; for the manufacture of a medicament for the prevention or the treatment of inflammatory and/or auto-immune diseases mediated through TNF-&#x3b1; and/or IL-12 

Growing community of inventors

Beerse, Belgium

Julien Georges Pierre-Olivier Doyon